CEOP-R regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: R-CEOP; Rituximab/Cyclophosphamide/Epirubicin/Vincristine/Prednisone
Overview
CEOP-R regimen refers to an immunochemotherapy regimen consisting of cyclophosphamide, epirubicin, vincristine (Oncovin), prednisone and rituximab used to treat both indolent and aggressive forms of Diffuse large B-cell lymphoma.[1]
Regimen
CCyclophosphamide
EEpirubicin
OVincristine (Oncovin)
PPrednisone
RRituximab
Indications
References
- ↑ 1.0 1.1 Li Y, Yimamu M, Wang X, Zhang X, Mao M, Fu L; et al. (2014). “Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression”. Int J Hematol. 99 (1): 79–86. doi:10.1007/s12185-013-1472-z. PMID 24258714.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH